Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription 19.10.2026 4 BMC Cancer 2 Cancer Cell 1 Cancer Chemother Pharmacol 1 Cancer Epidemiol Biomarkers Prev 1 Cancer Res 1 Cancer Sci 1 Clin Cancer Res 5 Clin Lung Cancer 1 Eur J Cancer 1 Int J Cancer 1 Int J Oncol 2 Int J Radiat Oncol Biol Phys 1 J Clin Invest 2 J Clin Oncol 2 Lancet 14 Lung Cancer 1 Mol Carcinog 1 Oncol Rep 5 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

BMC Cancer

1. ISAKA T, Kaburaki Y, Takada I, Matsuyama R, et al
   A multicenter prediction model for false-positive clinical nodal disease in < 4-cm NSCLC: clinical implications for upfront surgery versus neoadjuvant therapy.
   BMC Cancer. 2026;26:1221.
   PubMed         Abstract available
   
   
2. RAO L, Lin H, Zhang G, Zu R, et al
   A new prognostic perspective on preoperative coagulation parameters for lung adenocarcinoma patients: development and validation of the DFP score.
   BMC Cancer. 2026;26:1219.
   PubMed         Abstract available
   
   
3. LIU C, Li T, Qin BY, Yu L, et al
   First-line treatment outcomes in HER2-altered advanced NSCLC: a real-world multi-center study comparing trastuzumab deruxtecan with conventional therapies and analysis by HER2/EGFR co-alteration status.
   BMC Cancer. 2026;26:1220.
   PubMed         Abstract available
   
   
4. HETTA HF, Zahran AM, Nabil EE, Elkady AA, et al
   Association of regulatory B, T cells and cytokine production with disease stage in non-small cell lung cancer patients: prospective case control study.
   BMC Cancer. 2026;26:1226.
   PubMed         Abstract available
   
   

   
   Cancer Cell

5. JI F, Zheng L, Chen D, Xia P, et al
   Myeloid reprogramming generates myeloid-derived activating cells to potentiate radiotherapy and suppress metastasis.
   Cancer Cell. 2026;44:2011-2028.
   PubMed         Abstract available
   
   
6. LE X, Wang J, Yu Y, Zhao Y, et al
   Firmonertinib in advanced non-small cell lung cancer with epidermal growth factor receptor P-loop and alphaC-helix compressing mutations.
   Cancer Cell. 2026 Oct 16:S1535-6108(26)00430-7. doi: 10.1016/j.ccell.2026.
   PubMed         Abstract available
   
   

   
   Cancer Chemother Pharmacol

7. ZHAO Y, Ma X, Liu X, Yan L, et al
   Antibody-drug conjugates in lung cancer: clinical development, therapeutic advances, and emerging challenges.
   Cancer Chemother Pharmacol. 2026;96:118.
   PubMed         Abstract available
   
   

   
   Cancer Epidemiol Biomarkers Prev

8. PUCILLO GD, Jue AC, Law CG, Patel SP, et al
   Machine Learning Identifies Community-Level Factors Associated with Lung Cancer Incidence.
   Cancer Epidemiol Biomarkers Prev. 2026.
   PubMed         Abstract available
   
   

   
   Cancer Res

9. HSU CH, Chen J, Donahue LR, Lee KJ, et al
   Regression-Associated Macrophages Recruit Natural Killer Cells That Constrain Targeted Therapy Resistance.
   Cancer Res. 2026;86:5130-5146.
   PubMed         Abstract available
   
   

   
   Cancer Sci

10. NOMURA N, Jimbo N, Nakanishi T, Ito Y, et al
    Spatial Atlas of Small Cell Lung Carcinoma Reveals Intratumoral Tumor-State Heterogeneity and an MMP12(+) Macrophage Niche.
    Cancer Sci. 2026 Oct 11:10.1111/cas.70555. doi: 10.1111/cas.70555.
    PubMed         Abstract available
    
    

    
    Clin Cancer Res

11. MILIZIANO D, Rotow JK, Lomibao M, Marinello A, et al
    Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry.
    Clin Cancer Res. 2026 Oct 14. doi: 10.1158/1078-0432.CCR-26-2942.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

12. KLEBER TJ, Copling SA, Kim AD, Marquez CP, et al
    Using Induction Chemoimmunotherapy as a Bridge to Definitive Local Therapy for Non-Metastatic NSCLC: Real-World Outcomes From a Comprehensive Cancer Center.
    Clin Lung Cancer. 2026;27:22-32.
    PubMed         Abstract available
    
    
13. LUO Y, Wang Y, Ren P, Li Y, et al
    SBRT Plus Nivolumab in Advanced NSCLC: A Phase II Multicenter Study With Exploratory Bone Metastases Subgroup Analysis.
    Clin Lung Cancer. 2026;27:59-68.
    PubMed         Abstract available
    
    
14. CHEN JM, Kang YF, Zeng YC, Luo JR, et al
    Rapid Lorlatinib Response in Lung Adenocarcinoma With a Novel Y Chromosome Intergenic ALK Fusion: A Case Report.
    Clin Lung Cancer. 2026;27:69-73.
    PubMed         Abstract available
    
    
15. ROTOW J, Malapelle U, Cuadras D, Lara N, et al
    MET Testing and Treatment Sequencing After Disease Progression on First-Line Osimertinib in Patients With EGFR-Mutated Advanced NSCLC and Acquired MET Overexpression and/or Amplification: A Global Real-World Study.
    Clin Lung Cancer. 2026;27:74-86.
    PubMed         Abstract available
    
    
16. KAWABATA K, Masuda K, Miura K, Saida Y, et al
    A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non-Small Cell Lung Cancer: JCOG2510 (PRIME-CRT).
    Clin Lung Cancer. 2026;27:39-43.
    PubMed         Abstract available
    
    

    
    Eur J Cancer

17. HONG MH, Shim BY, Kim CG, Kim YS, et al
    Lazertinib plus pemetrexed and carboplatin in patients with EGFR-mutant advanced non-small cell lung cancer after progression on lazertinib.
    Eur J Cancer. 2026;248:117774.
    PubMed         Abstract available
    
    

    
    Int J Cancer

18. GRIFFO R, Niedermaier B, Klotz LV, Schneider M, et al
    Real-World Experience With Multimodal Treatment of Resectable Stage II-III Non-Small Cell Lung Cancer: A Single Institutional Analysis.
    Int J Cancer. 2026 Oct 14. doi: 10.1002/ijc.70789.
    PubMed         Abstract available
    
    

    
    Int J Oncol

19. FENG C, Ji Y, Chen R, Chen Q, et al
    Disporum cantoniense suppresses non?small cell lung cancer through AMPK/mTOR/ULK1?mediated autophagy?dependent apoptosis.
    Int J Oncol. 2026;69:137.
    PubMed         Abstract available
    
    

    
    Int J Radiat Oncol Biol Phys

20. CHUN SG, Iyengar P, Rimner A, Amini A, et al
    American Radium Society Appropriate Use Criteria: Accelerated hypofractionated radiotherapy in the multidisciplinary management of locally-advanced non-small cell lung cancer ineligible for concurrent chemotherapy.
    Int J Radiat Oncol Biol Phys. 2026 Oct 13:S0360-3016(26)04337.
    PubMed         Abstract available
    
    
21. PANSE D, Simone CB 2nd, Shepherd A, Ohri N, et al
    Proton Therapy for Hemithoracic Pleural Irradiation: A Step Toward Safer Radiation Treatment.
    Int J Radiat Oncol Biol Phys. 2026;126:1273-1282.
    PubMed         Abstract available
    
    

    
    J Clin Invest

22. LI Y, Laimon YN, Cho H, Vivero M, et al
    Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation.
    J Clin Invest. 2026;136:e199454.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

23. RIVERA MP, Henderson LM
    Promise and Challenge of Personalized Lung Cancer Screening.
    J Clin Oncol. 2026 Oct 16:JCO2601951. doi: 10.1200/JCO-26-01951.
    PubMed        
    
    
24. SKOV-JEPPESEN SM, Kobylecki CJ, Egstrand S, Rasmussen TR, et al
    Development and Validation of a Blood Test Informed Risk Prediction Model for Lung Cancer-The Copenhagen Lung Cancer Risk Model (CPH-Lung).
    J Clin Oncol. 2026 Oct 12:JCO2502326. doi: 10.1200/JCO-25-02326.
    PubMed         Abstract available
    
    

    
    Lancet

25. WAGENER EDA, van Geffen WH
    Optimising standard of care in non-small-cell lung cancer trials.
    Lancet. 2026;408:1555-1556.
    PubMed        
    
    
26. XIONG A, Yao W, Zheng W, Yu Y, et al
    Optimising standard of care in non-small-cell lung cancer trials - Authors' reply.
    Lancet. 2026;408:1556.
    PubMed        
    
    

    
    Lung Cancer

27. LUO J, Lin S, Tang W, Guo R, et al
    TLS-related immune organization and regional IRF4 expression in pretreatment biopsies of advanced lung adenocarcinoma.
    Lung Cancer. 2026;221:109648.
    PubMed         Abstract available
    
    
28. MAFFEI E, Ciaparrone C, D'Ardia A, Gaeta S, et al
    Lung cytology in the diagnostic workflow: A real-world study of its clinical impact.
    Lung Cancer. 2026;221:109643.
    PubMed         Abstract available
    
    
29. YAO Z, Wang X, Zhang H, Huang Y, et al
    Trial-specific absolute disease-free survival effects of postoperative PD-1/PD-L1 blockade after complete resection of NSCLC: A systematic review.
    Lung Cancer. 2026;221:109642.
    PubMed         Abstract available
    
    
30. HIRANO Y, Yagishita S, Shinno Y, Goto Y, et al
    Exploratory analysis of extracellular vesicle Profile changes during pembrolizumab treatment in NSCLC.
    Lung Cancer. 2026;221:109640.
    PubMed         Abstract available
    
    
31. EYSHA M, Green A, Khamis MM, Arai M, et al
    Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC.
    Lung Cancer. 2026;221:109634.
    PubMed         Abstract available
    
    
32. ROBLES AP, Christopoulos P, Allgauer M, Kluck K, et al
    Longitudinal transcriptomic profiling of paired early and metastatic EGFR-mutant lung adenocarcinomas reveals molecular programs associated with disease progression.
    Lung Cancer. 2026;221:109628.
    PubMed         Abstract available
    
    
33. ZHAO K, Zhou Q, Nie X, Chen Y, et al
    Pathological complete necrosis after pulmonary thermal ablation: a systematic review and meta-analysis of ablate-and-resect studies.
    Lung Cancer. 2026;221:109631.
    PubMed         Abstract available
    
    
34. HOOPER C, Anderson M, Jones SB, Faivre-Finn C, et al
    The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion.
    Lung Cancer. 2026;221:109602.
    PubMed         Abstract available
    
    
35. ASSIE JB, Greillier L, Gobert A, Falchero L, et al
    Long-term real-world outcomes of nivolumab+ipilimumab treatment of unresectable pleural mesothelioma: update of Meso-Immune GFPC 04-2021 study.
    Lung Cancer. 2026;221:109622.
    PubMed         Abstract available
    
    
36. ZHAO D, Xie D, Zhang L, Zhang N, et al
    Molecular concordance and clonal dynamics of KRAS mutations in lung adenocarcinoma across distinct clinical scenarios.
    Lung Cancer. 2026;221:109597.
    PubMed         Abstract available
    
    
37. HE L, Xu X, Bi L, Ji C, et al
    Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC grading.
    Lung Cancer. 2026;221:109591.
    PubMed         Abstract available
    
    
38. COWELL GW, Roche J, Noble C, Stobo DB, et al
    Discordance in pleural mesothelioma response classification and modelling of impact on clinical trials.
    Lung Cancer. 2026;221:109624.
    PubMed         Abstract available
    
    
39. ANDO T, Fujii K, Ikushima H, Watanabe K, et al
    Standard targeted therapy implementation for driver alterations newly identified by comprehensive genomic profiling in clinically driver-negative advanced NSCLC.
    Lung Cancer. 2026;221:109625.
    PubMed         Abstract available
    
    
40. ZHANG M, Guo M, Li L, Qu C, et al
    First-line camrelizumab plus chemotherapy followed by camrelizumab-apatinib maintenance for ES-SCLC: a single-arm phase II study.
    Lung Cancer. 2026;221:109623.
    PubMed         Abstract available
    
    

    
    Mol Carcinog

41. MENG L, Xie S, Li K, Zhao X, et al
    USP26 Promotes Non-Small Cell Lung Cancer Progression via Deubiquitination and Stabilization of Galphas.
    Mol Carcinog. 2026 Oct 13. doi: 10.1002/mc.70194.
    PubMed         Abstract available
    
    

    
    Oncol Rep

42. XU Z, Shen J, Lin Y, Shi H, et al
    CHCHD2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma: Insights from pan?cancer multi?omics and functional studies.
    Oncol Rep. 2026;56:207.
    PubMed         Abstract available
    
    

    
    PLoS One

43. TRAN K, Chen E, Symmans WF, Sura GH, et al
    Quantifying the diagnostic time gap in precision oncology: A retrospective analysis of potential time savings from same-day cartridge-based molecular testing versus next-generation sequencing in cytology specimens.
    PLoS One. 2026;21:e0360239.
    PubMed         Abstract available
    
    
44. DAS S, Kundu S, Tanny SJ
    Stage-driven mortality and clinical risk stratification among lung cancer patients in Dhaka, Bangladesh: A multi-hospital secondary analysis.
    PLoS One. 2026;21:e0359406.
    PubMed         Abstract available
    
    
45. XU Y, Hao J, Dou Y, Zeng B, et al
    Predicting lymph node metastasis in non-small cell lung cancer using clinical and PET/CT-derived morphological features: An interpretable machine-learning study.
    PLoS One. 2026;21:e0361043.
    PubMed         Abstract available
    
    
46. LEE KA, Borah A, Fiscus G, Petricca L, et al
    Real-world before-and-after evaluation of AI support for lung cancer diagnosis at three US lung nodule clinics.
    PLoS One. 2026;21:e0358655.
    PubMed         Abstract available
    
    
47. DA S, B RN
    ReViT-RF: A hybrid ResNet-50-Vision Transformer with a Radiomic Feature Fusion framework for lung tumor classification and TNM-based stage prediction using CT images.
    PLoS One. 2026;21:e0359211.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum